Ossio, a Caesarea, Israel- and Woburn, MA-based orthopedic fixation technology company, raised $38.5M in Series C funding.
The round was led by MVM Partners. Dr. Reeders and his MVM colleague Dr. Kevin Cheng join OSSIO’s board of directors as part of this financing. MVM’s Dr. Stephen Reeders and his MVM colleague Dr. Kevin Cheng join OSSIO’s board of directors as part of this financing.
The company intends to use the funds to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber implants and accelerate new product platforms into the major orthopedic fixation markets.
Led by CEO Brian Verrier, Ossio is an orthopedic fixation company committed to improving the orthopedic experience for patients, physicians and payors. Founded in 2014, the company leverages the OSSIOfiber Intelligent Bone Regeneration Technology to create implants made from a proprietary mineral fiber matrix held together by a naturally degradable polymer. The technology features bio-integrative material properties that provide surgeons with a biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind.
More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019.
Ossio’s development headquarters is located in Caesarea, Israel, and its US headquarters is in Woburn, MA.
FinSMEs
18/10/2022